REG - Faron Pharma. Oy - Notice of Half-Year Financial Results

Faron Pharmaceuticals OyAnnouncement

20/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240820:nRST9800Aa&default-theme=true

RNS Number : 9800A  Faron Pharmaceuticals Oy  20 August 2024

Faron Pharmaceuticals Ltd.

("Faron" or the "Company")

 

Faron Pharmaceuticals

Notice of Half-Year Financial Results

 

Company Announcement, 20 August 2024

 

TURKU, Finland - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company pursuing a CLEVER approach to
reprogramming myeloid cells to activate anti-tumor immunity in hematological
and solid tumor microenvironments, will report its unaudited half-year
financial results for the six months ended June 30, 2024, on Tuesday, 27
August 2024.

 

A live hybrid briefing and Q&A session for investors, analysts and media
will be hosted by Dr. Juho Jalkanen, Chief Executive Officer, and Yrjö
Wichmann, Chief Financial Officer, at 08:00 am (EDT) / 13:00 pm (BST) / 15:00
pm (EEST) on Wednesday, 28 August 2024.

 

Webcast registration link: https://faron.videosync.fi/q2-2024
(https://url.us.m.mimecastprotect.com/s/NF_DCR6MPEIJKl56T9fzuAL6aL?domain=faron.videosync.fi)

 

Live participation

In addition to the webcast, there are a number of spaces available to attend
the briefing in-person at Studio Eliel in Sanomatalo at Töölönlahdenkatu 2,
Helsinki. To register, please contact

investor.relations@faron.com (mailto:investor.relations@faron.com) no later
than 10:00 a.m. EEST on Monday, 26 August 2024. Please note that places are
limited, and you will receive a separate email confirmation.

 

The half-year report, presentation, and a replay of the webcast will be
available on the Company's website at www.faron.com/investors
(http://www.faron.com/investors) .

 

 

For more information please contact:

 

Investor Contact

Faron Pharmaceuticals
E-mail: investor.relations@faron.com

 

Media Contact

ICR Consilium

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

About BEXMAB

The BEXMAB study is an open-label Phase 1/2 clinical trial
investigating bexmarilimab in combination with standard of care (SoC) in the
aggressive hematological malignancies of acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS). The primary objective is to determine the
safety and tolerability of bexmarilimab in combination with SoC (azacitidine)
treatment. Directly targeting Clever-1 could limit the replication capacity of
cancer cells, increase antigen presentation, ignite an immune response, and
allow current treatments to be more effective. Clever-1 is highly expressed in
both AML and MDS and associated with therapy resistance, limited T cell
activation and poor outcomes.

 

About Bexmarilimab

Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed
to overcome resistance to existing treatments and optimize clinical outcomes,
by targeting myeloid cell function and igniting the immune
system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found
on macrophages leading to tumor growth and metastases (i.e. helps cancer evade
the immune system). By targeting the Clever-1 receptor on
macrophages, bexmarilimab alters the tumor microenvironment, reprogramming
macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1)
one, upregulating interferon production and priming the immune system to
attack tumors and sensitizing cancer cells to standard of care.

 

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through reprogramming myeloid cell
function. Bexmarilimab is being investigated in Phase I/II clinical trials
as a potential therapy for patients with hematological cancers in combination
with other standard treatments. Further information is available
at www.faron.com (http://www.faron.com/) .

 

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be,
forward-looking statements. Forward looking statements are identified by their
use of terms and phrases such as ''believe'', ''could'', "should", "expect",
"hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'',
''potentially'', ''will'' or the negative of those, variations or comparable
expressions, including references to assumptions. These forward-looking
statements are not based on historical facts but rather on the Directors'
current expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof), competitive
advantages, business prospects and opportunities. Such forward-looking
statements reflect the Directors' current beliefs and assumptions and are
based on information currently available to the Directors.

 

A number of factors could cause actual results to differ materially from the
results and expectations discussed in the forward-looking statements, many of
which are beyond the control of the Company. In addition, other factors which
could cause actual results to differ materially include the ability of the
Company to successfully license its programs within the anticipated timeframe
or at all, risks associated with vulnerability to general economic and
business conditions, competition, environmental and other regulatory changes,
actions by governmental authorities, the availability of capital markets or
other sources of funding, reliance on key personnel, uninsured and
underinsured losses and other factors. Although any forward-looking statements
contained in this announcement are based upon what the Directors believe to be
reasonable assumptions, the Company cannot assure investors that actual
results will be consistent with such forward-looking statements. Accordingly,
readers are cautioned not to place undue reliance on forward-looking
statements. Subject to any continuing obligations under applicable law or any
relevant AIM Rule requirements, in providing this information the Company does
not undertake any obligation to publicly update or revise any of the
forward-looking statements or to advise of any change in events, conditions or
circumstances on which any such statement is based.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFLFFETVIALIS